Selection of exams at diagnosis and during follow-up according to the risk of disease progression.

Flow chart describing the successive steps during the selection of eligible studies.

Theodoros N. Sergentanis (499872)
Georgios Tsivgoulis (665231)
Christina Perlepe (791174)
Ioannis Ntanasis-Stathopoulos (791175)
Ioannis-Georgios Tzanninis (791176)
Ioannis N. Sergentanis (791177)
Theodora Psaltopoulou (779638)

September 2015

Flow chart describing the successive steps during the selection of eligible studies.</p

Attributes and levels assigned to preventive treatments currently under study.

Mark Harrison (4222480)
Luke Spooner (3545009)
Nick Bansback (185069)
Katherine Milbers (6635777)
Cheryl Koehn (5950853)
Kam Shojania (6635780)
Axel Finckh (3918683)
Marie Hudson (289434)

April 2019

Attributes and levels assigned to preventive treatments currently under study.</p

Distribution of study population according to eligibility at entry into care or later, treatment initiation during the follow-up in CTA and period at entry.

Ndeye Fatou Ngom (5770661)
Mame Awa Faye (5770664)
Kiné Ndiaye (5770667)
Aminata Thiam (5770670)
Cheikh Tidiane Ndour (5770673)
Jean-François Etard (123661)
Papa Salif Sow (135540)
Moussa Seydi (163879)
Eric Delaporte (284745)
Amandine Cournil (262971)

September 2018

Distribution of study population according to eligibility at entry into care or later, treatment ini...

Input probabilities for subsequent diagnostic procedures arranged when further information was needed at each imaging.

Xiaoning He (397446)
Jing Wu (54032)
Anke-Peggy Holtorf (4760481)
Harald Rinde (4760478)
Shuangshuang Xie (783228)
Wen Shen (624469)
Jiancun Hou (4760484)
Xuehua Li (1719874)
Ziping Li (4760487)
Jiaming Lai (415220)
Yuting Wang (434390)
Lin Zhang (8926)
Jian Wang (5901)
Xuesong Li (291235)
Kuansheng Ma (291469)
Feng Ye (173489)
Han Ouyang (709961)
Hong Zhao (325)

January 2018

Input probabilities for subsequent diagnostic procedures arranged when further information was ne...

Selection and operationalization of chronic morbidity and its distribution across the sample.

Fabiola Müller (3712783)
Mariët Hagedoorn (3399545)
Marrit A. Tuinman (3712780)

February 2017

Selection and operationalization of chronic morbidity and its distribution across the sample.</p

Selection of the study population and distribution according to eligibility at entry into care or later and treatment initiation during the follow-up in CTA.

Ndeye Fatou Ngom (5770661)
Mame Awa Faye (5770664)
Kiné Ndiaye (5770667)
Aminata Thiam (5770670)
Cheikh Tidiane Ndour (5770673)
Jean-François Etard (123661)
Papa Salif Sow (135540)
Moussa Seydi (163879)
Eric Delaporte (284745)
Amandine Cournil (262971)

September 2018

Selection of the study population and distribution according to eligibility at entry into care or la...

Disease severity, outcome and supportive care over the course of the study.

James D. Stewart (362315)
Simon Smith (675188)
Enzo Binotto (3815149)
William J. McBride (1593391)
Bart J. Currie (131288)
Josh Hanson (342079)

March 2017

Disease severity, outcome and supportive care over the course of the study.</p

Sensitivity and specificity of diagnostic tests, probabilities of treatment success and epidemiology of diseases.

Mari Kajiwara Saito (5987981)
Christopher M. Parry (349451)
Shunmay Yeung (53391)

December 2018

Sensitivity and specificity of diagnostic tests, probabilities of treatment success and epidemiology...

Medical complications and medications types that the study subjects taking during the follow-up times.

Adeladlew Kassie Netere (4621486)
Ashenafi Kibret Sendekie (12646960)

September 2022

Medical complications and medications types that the study subjects taking during the follow-up time...

The incidence of subsequent short-term and long-term morbidity stratified by follow-up period.

Kai-Biao Lin (4856752)
Nan-Ping Yang (16160)
Yi-Hui Lee (1455238)
Chien-Lung Chan (748298)
Chi-Hsu Wu (4856755)
Hou-Chuan Chen (4856758)
Nien-Tzu Chang (4856761)

February 2018

The incidence of subsequent short-term and long-term morbidity stratified by follow-up period.</p

Cohort enrolment, treatment and follow up and decision making for progression to screening of the next intensity of infection cohort within one dose group (A) and for progression to screening for the mildly infected cohort at the next higher dose level (B).

Kwablah Awadzi (169148)
Nicholas O. Opoku (589134)
Simon K. Attah (226315)
Janis Lazdins-Helds (589135)
Annette C. Kuesel (589136)

June 2014

Cohort enrolment, treatment and follow up and decision making for progression to screening of the...

Predictive evaluation of the best parameters to show complication of disease.

Gulsum Feyza Turkes (14290161)
Abdulkadir Unsal (9936836)
Hakan Bulus (14290164)

December 2022

Predictive evaluation of the best parameters to show complication of disease.</p

Prevalence of feasible studies by chronic disease continuum targeted health actions.

Temitope Ojo (6391868)
Lynette Lester (6391871)
Juliet Iwelunmor (770171)
Joyce Gyamfi (3293661)
Chisom Obiezu-Umeh (6391874)
Deborah Onakomaiya (6391877)
Angela Aifah (3805093)
Shreya Nagendra (6391880)
Jumoke Opeyemi (6391883)
Mofetoluwa Oluwasanmi (6391886)
Milena Dalton (6391889)
Ucheoma Nwaozuru (6391892)
Dorice Vieira (6391895)
Gbenga Ogedegbe (530876)
Bernadette Boden-Albala (6391898)

February 2019

Prevalence of feasible studies by chronic disease continuum targeted health actions.</p

rs1801157 genotypes and risk of disease progression according to different time period.

Ketty Gianesin (309061)
Riccardo Freguja (309062)
Francesco Carmona (309063)
Marisa Zanchetta (309064)
Paola Del Bianco (55772)
Sandro Malacrida (309065)
Marco Montagna (238698)
Osvalda Rampon (309066)
Carlo Giaquinto (309067)
Anita De Rossi (309068)

February 2013

rs1801157 genotypes and risk of disease progression according to different time period.</p

Cumulative risk of a new diagnosis of any type of cancer following primary hip replacement by bearing type with numbers at risk shown.

Linda P. Hunt (5775326)
Ashley W. Blom (800084)
Gulraj S. Matharu (582631)
Martyn L. Porter (5775329)
Michael R. Whitehouse (800083)

September 2018

Cumulative risk of a new diagnosis of any type of cancer following primary hip replacement by bearin...

Flow chart describing the successive steps during the selection of eligible studies.

Theodoros N. Sergentanis (499872)
Georgios Tsivgoulis (665231)
Christina Perlepe (791174)
Ioannis Ntanasis-Stathopoulos (791175)
Ioannis-Georgios Tzanninis (791176)
Ioannis N. Sergentanis (791177)
Theodora Psaltopoulou (779638)

September 2015

Flow chart describing the successive steps during the selection of eligible studies.</p

Attributes and levels assigned to preventive treatments currently under study.

Mark Harrison (4222480)
Luke Spooner (3545009)
Nick Bansback (185069)
Katherine Milbers (6635777)
Cheryl Koehn (5950853)
Kam Shojania (6635780)
Axel Finckh (3918683)
Marie Hudson (289434)

April 2019

Attributes and levels assigned to preventive treatments currently under study.</p

Distribution of study population according to eligibility at entry into care or later, treatment initiation during the follow-up in CTA and period at entry.

Ndeye Fatou Ngom (5770661)
Mame Awa Faye (5770664)
Kiné Ndiaye (5770667)
Aminata Thiam (5770670)
Cheikh Tidiane Ndour (5770673)
Jean-François Etard (123661)
Papa Salif Sow (135540)
Moussa Seydi (163879)
Eric Delaporte (284745)
Amandine Cournil (262971)

September 2018

Distribution of study population according to eligibility at entry into care or later, treatment ini...

Input probabilities for subsequent diagnostic procedures arranged when further information was needed at each imaging.

Xiaoning He (397446)
Jing Wu (54032)
Anke-Peggy Holtorf (4760481)
Harald Rinde (4760478)
Shuangshuang Xie (783228)
Wen Shen (624469)
Jiancun Hou (4760484)
Xuehua Li (1719874)
Ziping Li (4760487)
Jiaming Lai (415220)
Yuting Wang (434390)
Lin Zhang (8926)
Jian Wang (5901)
Xuesong Li (291235)
Kuansheng Ma (291469)
Feng Ye (173489)
Han Ouyang (709961)
Hong Zhao (325)

January 2018

Input probabilities for subsequent diagnostic procedures arranged when further information was ne...

Selection and operationalization of chronic morbidity and its distribution across the sample.

Fabiola Müller (3712783)
Mariët Hagedoorn (3399545)
Marrit A. Tuinman (3712780)

February 2017

Selection and operationalization of chronic morbidity and its distribution across the sample.</p

Selection of the study population and distribution according to eligibility at entry into care or later and treatment initiation during the follow-up in CTA.

Ndeye Fatou Ngom (5770661)
Mame Awa Faye (5770664)
Kiné Ndiaye (5770667)
Aminata Thiam (5770670)
Cheikh Tidiane Ndour (5770673)
Jean-François Etard (123661)
Papa Salif Sow (135540)
Moussa Seydi (163879)
Eric Delaporte (284745)
Amandine Cournil (262971)

September 2018

Selection of the study population and distribution according to eligibility at entry into care or la...

Disease severity, outcome and supportive care over the course of the study.

James D. Stewart (362315)
Simon Smith (675188)
Enzo Binotto (3815149)
William J. McBride (1593391)
Bart J. Currie (131288)
Josh Hanson (342079)

March 2017

Disease severity, outcome and supportive care over the course of the study.</p

Sensitivity and specificity of diagnostic tests, probabilities of treatment success and epidemiology of diseases.

Mari Kajiwara Saito (5987981)
Christopher M. Parry (349451)
Shunmay Yeung (53391)

December 2018

Sensitivity and specificity of diagnostic tests, probabilities of treatment success and epidemiology...

Medical complications and medications types that the study subjects taking during the follow-up times.

Adeladlew Kassie Netere (4621486)
Ashenafi Kibret Sendekie (12646960)

September 2022

Medical complications and medications types that the study subjects taking during the follow-up time...

The incidence of subsequent short-term and long-term morbidity stratified by follow-up period.

Kai-Biao Lin (4856752)
Nan-Ping Yang (16160)
Yi-Hui Lee (1455238)
Chien-Lung Chan (748298)
Chi-Hsu Wu (4856755)
Hou-Chuan Chen (4856758)
Nien-Tzu Chang (4856761)

February 2018

The incidence of subsequent short-term and long-term morbidity stratified by follow-up period.</p

Cohort enrolment, treatment and follow up and decision making for progression to screening of the next intensity of infection cohort within one dose group (A) and for progression to screening for the mildly infected cohort at the next higher dose level (B).

Kwablah Awadzi (169148)
Nicholas O. Opoku (589134)
Simon K. Attah (226315)
Janis Lazdins-Helds (589135)
Annette C. Kuesel (589136)

June 2014

Cohort enrolment, treatment and follow up and decision making for progression to screening of the...

Predictive evaluation of the best parameters to show complication of disease.

Gulsum Feyza Turkes (14290161)
Abdulkadir Unsal (9936836)
Hakan Bulus (14290164)

December 2022

Predictive evaluation of the best parameters to show complication of disease.</p

Prevalence of feasible studies by chronic disease continuum targeted health actions.

Temitope Ojo (6391868)
Lynette Lester (6391871)
Juliet Iwelunmor (770171)
Joyce Gyamfi (3293661)
Chisom Obiezu-Umeh (6391874)
Deborah Onakomaiya (6391877)
Angela Aifah (3805093)
Shreya Nagendra (6391880)
Jumoke Opeyemi (6391883)
Mofetoluwa Oluwasanmi (6391886)
Milena Dalton (6391889)
Ucheoma Nwaozuru (6391892)
Dorice Vieira (6391895)
Gbenga Ogedegbe (530876)
Bernadette Boden-Albala (6391898)

February 2019

Prevalence of feasible studies by chronic disease continuum targeted health actions.</p

rs1801157 genotypes and risk of disease progression according to different time period.

Ketty Gianesin (309061)
Riccardo Freguja (309062)
Francesco Carmona (309063)
Marisa Zanchetta (309064)
Paola Del Bianco (55772)
Sandro Malacrida (309065)
Marco Montagna (238698)
Osvalda Rampon (309066)
Carlo Giaquinto (309067)
Anita De Rossi (309068)

February 2013

rs1801157 genotypes and risk of disease progression according to different time period.</p

Cumulative risk of a new diagnosis of any type of cancer following primary hip replacement by bearing type with numbers at risk shown.

Linda P. Hunt (5775326)
Ashley W. Blom (800084)
Gulraj S. Matharu (582631)
Martyn L. Porter (5775329)
Michael R. Whitehouse (800083)

September 2018

Cumulative risk of a new diagnosis of any type of cancer following primary hip replacement by bearin...

Flow chart describing the successive steps during the selection of eligible studies.

Theodoros N. Sergentanis (499872)
Georgios Tsivgoulis (665231)
Christina Perlepe (791174)
Ioannis Ntanasis-Stathopoulos (791175)
Ioannis-Georgios Tzanninis (791176)
Ioannis N. Sergentanis (791177)
Theodora Psaltopoulou (779638)

September 2015

Flow chart describing the successive steps during the selection of eligible studies.</p

Attributes and levels assigned to preventive treatments currently under study.

Mark Harrison (4222480)
Luke Spooner (3545009)
Nick Bansback (185069)
Katherine Milbers (6635777)
Cheryl Koehn (5950853)
Kam Shojania (6635780)
Axel Finckh (3918683)
Marie Hudson (289434)

April 2019

Attributes and levels assigned to preventive treatments currently under study.</p

Distribution of study population according to eligibility at entry into care or later, treatment initiation during the follow-up in CTA and period at entry.

Ndeye Fatou Ngom (5770661)
Mame Awa Faye (5770664)
Kiné Ndiaye (5770667)
Aminata Thiam (5770670)
Cheikh Tidiane Ndour (5770673)
Jean-François Etard (123661)
Papa Salif Sow (135540)
Moussa Seydi (163879)
Eric Delaporte (284745)
Amandine Cournil (262971)

September 2018

Distribution of study population according to eligibility at entry into care or later, treatment ini...

Selection of exams at diagnosis and during follow-up according to the risk of disease progression.

Abstract

Extracted data

Selection of exams at diagnosis and during follow-up according to the risk of disease progression.

Abstract

Extracted data

Related items

Related items